study reveals that SGLT2 inhibitors consistently lower the risk of major adverse cardiovascular events by 9% across various patient groups, especially impacting cardiovascular death reduction, highlighting their broad therapeutic potential beyond diabetes management.
KLAS: Cognizant & HealthEdge Leads Marker for Payer Claims & Administration Platforms
What You Should Know: In recent years, the complex payer claims and administration market has seen several changes. Historically, payers have used multiple technology vendors
August 28, 2023